Technology
Health
Pharmaceutical
Provention Bio
$3.779876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.04 (-1.05%) Today
+$0.01 (0.27%) After Hours
Why Robinhood?
You can buy or sell Provention Bio and other stocks, options, ETFs, and crypto commission-free!
About
Provention Bio, Inc. Common Stock, also called Provention Bio, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Read More Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn's disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.
Employees
13
Headquarters
Lebanon, New Jersey
Founded
2016
Market Cap
141.97M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
60.31K
High Today
$3.81
Low Today
$3.66
Open Price
$3.75
Volume
36.61K
52 Week High
$8.00
52 Week Low
$1.52
Collections
Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2018 IPO
US
News
Markets InsiderMay 8
Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
OLDWICK, N.J., May 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced preliminary top-line results from its Phase 1b PULSE study which evaluated PRV-300, an anti-TLR3 (toll-like receptor 3) monoclonal antibody, in patients with active, moderate-to-severe ulcerative colitis (UC). PRV-300 met the primary safety and tolerability endpoint over the twelve-week study period and ...
Price Paid on Robinhood
14% Higher
Right Now
52 Week Low
$1.52
Average Price Paid
$3.32
52 Week High
$8.00
Earnings
-$1.05
-$0.75
-$0.45
-$0.15
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 13, After Hours